Press releases
- BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
- BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- BioLineRx to Report First Quarter 2024 Results on May 28, 2024
- BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
- BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
More ▼
Key statistics
As of last trade, BioLine RX Ltd (YP2A:MUN) traded at 0.65, 20.37% above the 52 week low of 0.540 set on Jul 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.65 |
---|---|
High | 0.65 |
Low | 0.65 |
Bid | 0.685 |
Offer | 0.735 |
Previous close | 0.61 |
Average volume | 71.11 |
---|---|
Shares outstanding | 79.94m |
Free float | 79.94m |
P/E (TTM) | -- |
Market cap | 57.60m USD |
EPS (TTM) | -0.7628 USD |
Data delayed at least 15 minutes, as of Jul 16 2024 07:04 BST.
More ▼